December 23, 2003Arteriosclerosis Thrombosis and Vascular Biology
5 Years of Insulin Therapy With Insulin Glargine Improves In Vivo Endothelial Function in Type 2 Diabetes
Key result
Insulin glargine therapy for 3.5 years significantly improved endothelium-dependent vasodilatation in patients with type 2 diabetes, increasing high-dose ACh blood flow by 86% (P<0.01 vs baseline).
Why the study?
Does long-term combination therapy with insulin glargine and metformin improve in vivo endothelial function in patients with type 2 diabetes?
Population
11 patients with type 2 diabetes, 16 matched normal subjects, and a control group of type 2 diabetic…
Comparison
Combination therapy with insulin glargine and… vs Type 2 diabetic patients not treated with…
Design
Cohort
Follow-up
3.5 years
Authors
Discussion
Loading...
Member takes
Implication
May improve endothelial function in T2D; hypothesis-generating and requires RCT confirmation before practice change.
Study Design
Type
Cohort (n=27)
Structured PICO
Does long-term combination therapy with insulin glargine and metformin improve in vivo endothelial function in patients with type 2 diabetes?
P
Population
11 patients with type 2 diabetes and 16 matched normal subjects evaluated for endothelial function over 3.5 years of insulin glargine therapy.
E
Exposure
Combination therapy with insulin glargine and metformin for up to 3.5 years.
C
Comparator
Type 2 diabetic patients not treated with insulin (studied at 6-month intervals) and matched normal subjects.
O
Outcome
In vivo endothelial function measured by blood flow during intrabrachial artery infusions of endothelium-dependent (acetylcholine) and endothelium-independent (sodium nitroprusside) vasoactive agents.surrogate
Main Result
p-value: p=<0.01
Long-term therapy with insulin glargine and metformin significantly improves both endothelium-dependent and endothelium-independent vasodilatation in patients with type 2 diabetes.
Cite This Study
Vehkavaara et al. (2003) conducted a cohort in Type 2 diabetes (n=27). Insulin glargine and metformin vs. Normal subjects and non-insulin treated type 2 diabetic patients was evaluated on In vivo endothelial function (blood flow during acetylcholine and sodium nitroprusside infusions) (p=<0.01). Insulin glargine therapy for 3.5 years significantly improved endothelium-dependent vasodilatation in patients with type 2 diabetes, increasing high-dose ACh blood flow by 86% (P<0.01 vs baseline).